Welcome to our dedicated page for Ocugen news (Ticker: $OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocugen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocugen's position in the market.
Ocugen, a biotechnology company, announced Dr. Arun Upadhyay, CSO, will present at the Retina World Congress on modifier gene therapy. The company's abstract on gene therapy for retinitis pigmentosa has been accepted. Their Phase 3 clinical trial for OCU400 is progressing towards BLA and MAA approval by 2026.
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) has announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held on May 3, 2024 in Seattle, WA. The presentation will be about the safety and efficacy of Nuclear Hormone Receptor-Based Gene Modifier Therapy in Phase 1/2 Clinical Trials for Retinitis Pigmentosa.
The OCU400 Phase 3 liMeliGhT clinical trial is ongoing and is expected to meet the Company’s 2026 BLA and MAA approval targets. RP affects nearly 300,000 people in the U.S. and EU, and there is currently a significant unmet need for patients with this condition. Dr. Bakall believes that this approach can offer a new therapeutic option to address retinitis pigmentosa.
